SCHEMBL167634

SCHEMBL167634

Nc1ccc2c(c1)OC(F)(F)O2

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.55
KDM4E B2RXH2 3/20 0.55
GAA P10253 2/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
ALDH1A1 P00352 2/20 0.55
MITF O75030 1/20 0.55
MAPK1 P28482 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
KIF11 P52732 2/20 0.44
CTNNB1 P35222 3/20 0.41
WNT3A P56704 3/20 0.41
PIK3CA P42336 2/20 0.40
NOTUM Q6P988 1/20 0.40
PIK3CG P48736 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMYD3 Q9H7B4 2/20 0.39
HDAC4 P56524 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30888841 1.00 MAPT (0.55) MAPTKDM4EGAAMEN1KMT2A
Hydrochloric Acid SCHEMBL26914206 0.98 MAPT (0.58) MAPTKDM4EGAAMEN1KMT2A
SCHEMBL397438 0.86 MAPT (0.55) MAPTKDM4EGAAMEN1KMT2A
SCHEMBL3895990 0.84 KIF11 (0.58) MAPTKDM4EGAAMEN1KMT2A
SCHEMBL21497169 0.79 KIF11 (0.50) MAPTKDM4EGAAMEN1KMT2A
SCHEMBL11001363 0.78 MAPT (0.47) MAPTKDM4EGAAMEN1KMT2A
SCHEMBL10638306 0.78 MAPT (0.47) MAPTKDM4EGAAMEN1KMT2A
SCHEMBL19412781 0.78 MAPT (0.47) MAPTKDM4EGAAMEN1KMT2A
SCHEMBL14007740 0.78 MAPT (0.47) MAPTKDM4EGAAMEN1KMT2A
SCHEMBL7881729 0.77 MAPT (0.55) MAPTKDM4EGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 781 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122010969-A Aminated 20 (S) -10, 11-difluoro methylenedioxy camptothecin derivative, and preparation method and application thereof 浙江工业大学 2026-05-12 CN claimed
WO-2010017179-A1 CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF CHDI, INC. (US) 2010-02-11 WO claimed
US-20100009964-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-01-14 US claimed
EP-1848713-A2 AMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2007-10-31 EP claimed
JP-2007523865-A 2007-08-23 JP claimed
US-7259267-B2 Difluorobenzo-1,3-dioxoles LANXESS DEUTSCHLAND GMBH (DE) 2007-08-21 US claimed
US-7129235-B2 Amides useful for treating pain ABBOTT LABORATORIES (US) 2006-10-31 US claimed
US-20060116407-A1 Amide derivatives HOFFMANN-LA ROCHE INC. 2006-06-01 US claimed
WO-2006053778-A2 AMIDE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2006-05-26 WO claimed
EP-1646621-A2 NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN Abbott Laboratories (US) 2006-04-19 EP claimed
US-20060058372-A1 N-Benzodioxolyl, n-benzodioxanyl and n-benzodioxepinyl arylcarboxamide derivatives and pharmaceutical compositions comprising them MERCK PATENT GMBH (DE) 2006-03-16 US claimed
EP-1554263-A1 N-BENZODIOXOLYL, N-BENZODIOXANYL AND N-BENZODIOXEPINYL ARYLCARBONXAMIDE DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM MERCK PATENT GmbH (DE) 2005-07-20 EP claimed
US-20050080095-A1 administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I ABBVIE INC. 2005-04-14 US claimed
WO-2005007642-A2 NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN ABBOTT LABORATORIES (US) 2005-01-27 WO claimed
WO-2004037806-A1 N-BENZODIOXOLYL, N-BENZODIOXANYL AND N-BENZODIOXEPINYL ARYLCARBONXAMIDE DERIVATIVES, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM MERCK PATENT GMBH (DE) 2004-05-06 WO claimed
WO-2026102082-A1 ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE DEEP APPLE THERAPEUTICS, INC. (US) 2026-05-15 WO disclosed
US-20260132119-A1 Alkylphenyl Substituted Compounds, Compositions and Methods of Use DEEP APPLE THERAPEUTICS, INC. (US) 2026-05-14 US disclosed
US-4246276-A Combating pests with 2,2-difluoro-5-(2,4-dinitro-6-trifluoromethylphenylamino)-benzodioxoles BAYER AKTIENGESELLSCHAFT (DE) 1981-01-20 US disclosed
EP-0011179-A2 N-phenyl ureas, process for their preparation, their use as herbicides, as well as intermediate products and their preparation BAYER AG (DE) 1980-05-28 EP disclosed
EP-0005756-A2 5-Arylamino-2,2-difluoro-benzodioxolanes, process for their preparation, and their use as pesticides BAYER AG (DE) 1979-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009964-A1 Compounds Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 MAPT 3811/4885KDM4E 3926/4885GAA 4103/4885
US-20060116407-A1 Amide derivatives GLS, SDHA, GLS2 MAPT 3340/4885KDM4E 2751/4885GAA 422/4885
US-20050080095-A1 administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I TRPV1, OPRL1, TRPV6 MAPT 4422/4885KDM4E 2816/4885GAA 2594/4885
US-20260132119-A1 Alkylphenyl Substituted Compounds, Compositions and Methods of Use GIPR, MC2R, GRPR MAPT 4716/4885KDM4E 3829/4885GAA 633/4885
US-20060058372-A1 N-Benzodioxolyl, n-benzodioxanyl and n-benzodioxepinyl arylcarboxamide derivatives and pharmaceutical compositions comprising them TBXAS1, PCSK9, APOB MAPT 4636/4885KDM4E 1667/4885GAA 1374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.